APLS Relative Valuation
APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.
Historical Valuation
Apellis Pharmaceuticals Inc (APLS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.70 is considered Undervalued compared with the five-year average of -19.53. The fair price of Apellis Pharmaceuticals Inc (APLS) is between 59.61 to 69.88 according to relative valuation methord. Compared to the current price of 17.42 USD , Apellis Pharmaceuticals Inc is Undervalued By 70.78%.
Relative Value
Fair Zone
59.61-69.88
Current Price：17.42
70.78%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
13.97
P/B
Median3y
21.67
Median5y
16.74
-0.37
FCF Yield
Median3y
-7.98
Median5y
-8.58
Competitors Valuation Multiple
The average P/S ratio for APLS's competitors is 29.10, providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of 2.70, which is -90.73% above the industry average. Given its robust revenue growth of -3.21%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Apellis Pharmaceuticals Inc (APLS) currently overvalued or undervalued?
What is Apellis Pharmaceuticals Inc (APLS) fair value?
How does APLS's valuation metrics compare to the industry average?
What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Jul 08 2025?
What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Jul 08 2025?
What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Jul 08 2025?